

















































How to RESPOND to the quest to increase the
effectiveness of cardiac resynchronization
therapy?
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This editorial refers to ‘Contractility sensor-guided opti-
mization of cardiac resynchronization therapy: results
from the RESPOND-CRT trial’†, by J. Brugada et al., on
page 730.
Cardiac resynchronization therapy (CRT) is an electrical treatment
based on biventricular or left ventricular (LV)-only pacing that was
initially applied as a last-resort therapeutic solution for patients with
severe heart failure (HF) associated with left bundle branch block.
Despite the technical limitations of devices and leads in the first
phases of clinical use, the clinical use of CRT rapidly moved from un-
controlled evaluations to randomized controlled trials (RCTs) that
definitively validated its role in appropriately selected patients with
NYHA II–IV heart failure.1–3 Moreover, the favourable outcome of
appropriately selected patients implanted with a CRT device has
been confirmed in ‘real-world’ studies and in evaluations focused on
cost-effectiveness.4–6
As with any treatment, assessment of patient outcomes after CRT
differs from assessment of the percentage of patients who can be
classified as ‘responders’ on the basis of individual responses. A series
of investigations reported that the proportion of responders to CRT
is in the range of 57–67% among patients with moderate to severe
HF.3,7 The attempts to improve the response to CRT, evaluated in
terms of LV reverse remodelling, an endpoint used as a surrogate of
outcome, has prompted a series of studies aimed at identifying the
clinical, echocardiographic, and electrocardiographic profile of re-
sponders, identifying and quantifying LV dyssynchrony (by echo, mag-
netic resonance imaging, nuclear cardiology, etc.) and quantifying scar
tissue (as a marker of ‘non-correctable’ dyssynchrony and for appro-
priate LV lead positioning), assessing the relationship between acute
haemodynamic response and long-term response or outcome and
assessing the impact of tailoring of atrioventricular (AV) and
interventricular (VV) interval programming on indices of LV function,
response to CRT, and patient outcome.1–3,7
A series of data from clinical studies support the concept that in
acute evaluations AV delay optimization improves LV performance
and stroke volume by allowing adequate diastolic filling of the left ven-
ricle as well as reduction of diastolic mitral regurgitation.8 Similarly,
acute evaluations with Doppler echocardiography showed that VV
delay optimization may reduce or eliminate dyssynchrony and maxi-
mize cardiac output, with significant reduction of mitral regurgita-
tion.3,8 On the basis of this background, optimization of suboptimal
programming of AV and VV intervals could constitute the most com-
mon and most correctable variable that may lead to improvement of
response to CRT. Optimization and tailoring of AV and VV program-
ming has been traditionally done with use of echocardiographic tech-
niques, but this requires exhaustive, iterative sampling that cannot be
proposed for daily practice and does not constitute the standard of
most of the centres implanting CRT devices.3
The influence of echocardiographic optimization of patients im-
planted with CRT has been the subject of controlled studies9 and
one meta-analysis including data from 12 studies and 4356 patients
with evidence of no significant differences in clinical or echocardio-
graphic outcomes between patients who underwent AV and/or VV
delay optimization and patients who underwent empiric device pro-
gramming.8 This neutral effect was confirmed even when the meta-
analysis was done only on randomized studies, or on isolated AV
delay or VV delay optimizations.8 The changes in optimal setting with
regard to VV intervals between rest and exercise,10 as well as during
follow-up,11 might explain the limitation of optimization performed
at rest, at a single time point, before discharge.
In the present issue of the journal, Brugada and colleagues present
the results of RESPOND-CRT, a prospective, randomized, double-
blinded, multicentre, non-inferiority trial evaluating the effect of
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weekly, automatic CRT optimization based on a SonR contractility
sensor vs. an echo-guided optimization of AV and VV timings.12 The
SonR system uses an accelerometer sealed in the atrial lead to meas-
ure mechanical vibrations generated in the heart during isovolumetric
contractions which are correlated with LV dP/dtmax. The device proc-
esses these signals through a specific algorithm, with the result of
automatic optimization of AV and VV intervals, that in this study was
performed every week.
The primary efficacy endpoint of RESPOND-CRT was the 12-
month rate of clinical responders (patient alive, without HF-related
events, with improvement in functional class or quality of life). In a
population sample of 998 patients, the rate of response was high
(75.0% in the SonR group vs. 70.4% within the echo group). The non-
inferiority of SonR vs. echo-guided optimization was demonstrated,
but not its superiority. In the long term, no significant differences
were found in the composite of death or HF hospitalizations, while
the risk of first HF hospitalization was significantly reduced in the
SonR group.12 Other ancillary analyses were done and showed no
significant differences in reverse LV remodelling at 12 months, but a
significantly higher rate of responders in SonR patients with a history
of atrial fibrillation at baseline or with renal dysfunction.12 These ob-
servations have all the limitations of subgroup analysis but deserve
interest for more focused prospective evaluations. As is known, atrial
fibrillation in CRT may interfere with clinical response by decreasing
the percentage of biventricular pacing,6 requiring AV junction abla-
tion in order to achieve the same effects and outcome of patients
with sinus rhythm,13 but the impact of history of atrial fibrillation on
changes in optimal programming of AV and VV intervals is not
defined. In this regard, the study protocol of RESPOND-CRT, not
including repeated echocardiographic optimization, may have helped
to highlight a benefit in some patient subgroups, in relation to the
more frequent automatic optimization of AV and VV intervals per-
formed weekly in the SonR group.12 Chronic kidney disease (CKD) is
an important co-morbidity in HF patients, with a reported prevalence
of up to 55%14 with maintained CRT-related benefits in the case of
mild to moderate CKD, but with a higher risk of adverse out-
comes.5,14 Advanced CKD is a well-recognized independent pre-
dictor of cardiac mortality and HF hospitalization.14 In view of the
expected increase of patients affected by CKD that will occur in
western countries in parallel with progressive population ageing, it is
clinically necessary to investigate responses and outcomes of CRT in
the very complex setting of patients with advanced CKD, where mul-
tiple co-morbidities may co-exist.5,14
The role of CRT optimization with regard to outcomes is not clear
and probably involves complex assessment, since it has been re-
ported that baseline LV dP/dtmax rather than acute haemodynamic ef-
fects of biventricular pacing are predictive of the most relevant
clinical outcomes at 1 year.15 In the approach to these complex
Figure 1 The complex network of inter-related factors that that may condition and modulate a positive response to cardiac resynchronization
therapy (CRT) and/or an improvement in outcome after implant of a CRT device. AV, atrioventricular; CKD, chronic kidney disease; HF, heart failure;






































































.evaluations, we should stress that clinical outcome and clinical re-
sponse are different endpoints in the assessment of CRT recipients
and, moreover, may differ according to the setting where CRT has
been applied (moderate to severe HF, mild HF, pacing for bradycar-
dia in a patients with LV dysfunction, pacing following AV juction abla-
tion in permanent atrial fibrillation with LV dysfunction).2,16 The
article by Brugada and colleagues12 tried to answer the research
question of whether response can be improved by means of an RCT,
and the authors have to be congratulated for their efforts. However,
the multitude of inter-related factors that may condition and modu-
late either a positive response to CRT and/or an improvement in out-
come after implant of a CRT device with defibrillation capabilities
(Figure 1) suggest the need for multiparametric analyses performed
on large data sets, corresponding to so-called ‘big data’, taking into ac-
count the enormous amount of patient data that can nowadays be
collected, processed, and interpreted.
‘How to RESPOND to the quest to increase the effectiveness of
cardiac resynchronization therapy?’ More than 20 years after the pi-
oneering experiences that started the clinical use of CRT, the answer
to this burning question appears really challenging and will require
the synergetic convergence of efforts from different fields, ranging
from molecular biology and basic sciences to bioengineering, medical
informatics, imaging, electrophysiology, experimental cardiology, HF
pathophysiology, and, last but not least, clinical cardiology.
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